Elezanumab (development names AE12-1Y-QL and ABT-555) is a fully human monoclonal antibody developed by AbbVie against repulsive guidance molecule A (RGMa). It has been tested in people with multiple sclerosis and acute ischemic stroke.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.